Drug profile

The FDA adverse-event record for Monoclonal Antibody

45 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Monoclonal Antibody. Species, reactions, and outcomes follow.

#1191 of 2,679
by report volume (all drugs)
45
adverse-event reports
6.7%
death-coded share
Dog
most-reported species
Verify with FDA CVM →

Corpus placement

According to the FDA Center for Veterinary Medicine openFDA adverse-event extract, Monoclonal Antibody ranks #1182 of 2679 by total reports (45). Death-coded-share rank requires at least 50 reports. National dual: Milbemycin Oxime + Spinosad is #1 of 2679 drugs by total adverse-event reports (149,624) at death-coded-share rank 965 of 1130 drugs with at least 50 reports (2.3%); separately, Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) is #1 highest death-coded share at 97.8% (report rank #821).

149,624
Milbemycin Oxime + Spinosad reports (#1)
97.8%
Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) death share (#1)
#1182
This drug, reports of 2679

Report volume reflects how common a breed or drug is and how often owners and vets file — not actual risk. Death-coded share ranks are limited to entries with enough reports to be meaningful. The two maps do not agree at #1.

Release-over-release change

What changed in the latest FDA data snapshot

PlainBreed reconstructed the prior snapshot from dated openFDA partitions through 2025 Q4, then compared it with the 2026-07-27 openFDA export. Monoclonal Antibody has 45 reports now versus 43 in that prior snapshot: 2 more (4.7%).

Report change
+2
Death-coded reports
+0
Death-coded share
−0.3 pts

This compares reported-event counts in two source snapshots. It does not establish a change in real-world risk, product safety, or disease incidence.

Subscribe to Monoclonal Antibody changes

Signature read: death-coded share at 6.7% is the most distinctive stamp on Monoclonal Antibody's FDA AER row.

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
45
Total Reports
3
Deaths Reported
6.7%
Death-coded share of reports

Active Ingredients

Monoclonal Antibody

Administration Routes

UnknownParenteralSubcutaneousOther

Species Affected

Dog 42
Cat 3

Most Affected Breeds

Shih Tzu 6
Retriever - Labrador 6
Terrier - Yorkshire 3
Retriever - Golden 3
Chihuahua 2
Poodle - Miniature 2
Crossbred Feline/cat 2
Pit Bull 2
Boxer (German Boxer) 2
Corgi - Welsh Cardigan 1

Most Reported Reactions

Lack of efficacy - NOS 6
Vomiting 6
Other abnormal test result NOS 5
Diarrhoea 5
Ataxia 4
Lethargy (see also Central nervous system depression in 'Neurological') 4
Pruritus 4
Weight loss 4
Inappetence 3
Deafness 3
Vocalisation 3
Bacterial skin infection NOS 3

Outcome Breakdown

Outcome Unknown
19 (42.2%)
Recovered/Normal
12 (26.7%)
Ongoing
11 (24.4%)
Euthanized
2 (4.4%)
Died
1 (2.2%)

Monoclonal Antibody Adverse Event Insights

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

What to do with this drug

A report does not prove a drug caused the reaction; consult a veterinarian before acting on this data.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

openFDA Animal & Veterinary Adverse Events (FDA CVM) for Monoclonal Antibody (#1191 of 2,679 by report volume); death-coded 6.7%. PlainBreed drug row · death-coded share stamp 6.7% · vintage 2025.

Informational only. FDA adverse-event reports are voluntary and do not prove causation; consult a veterinarian before acting on them. Verify with FDA CVM →